Double‐conditioning regimen consisting of high‐dose thiotepa and melphalan with autologous stem cell rescue for high‐risk pediatric solid tumors: A second report-Reference-Cited by-同舟云学术

Double‐conditioning regimen consisting of high‐dose thiotepa and melphalan with autologous stem cell rescue for high‐risk pediatric solid tumors: A second report

Published:2019-08-08 Issue:11 Volume:66 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Okada Keiko¹^ORCID,Yamasaki Kai¹^ORCID,Nitani Chika¹,Fujisaki Hiroyuki¹,Osugi Yuko¹,Hara Junichi¹

Affiliation:

1. Department of Pediatric Hematology/OncologyOsaka City General Hospital Osaka Japan

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27953

Reference20 articles.

1. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors

2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

3. VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION

4. Pharmacokinetics of high-dose chemotherapy

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IV Joint Congress of RSPOH “Actual problems and prospects for the development of pediatric oncology and hematology in the Russian Federation – 2023”. Resolution on the results of the satellite symposium “Tepadina in oncohematology: forgotten opportunities and new horizons”;Russian Journal of Pediatric Hematology and Oncology;2024-01-16

2. High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors;Bone Marrow Transplantation;2022-11-03

3. Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation;Japanese Journal of Clinical Oncology;2022-02-05

4. High-dose melphalan-based chemotherapy and autologous stem-cell transplantation for high-risk osteosarcoma in children: A single-institute experience and review of the literature;Pediatric Hematology Oncology Journal;2021-12

5. Thiotepa–melphalan myeloablative therapy for high‐risk neuroblastoma;Pediatric Blood & Cancer;2021-03-31